IGHE and neoplasm: We report that despite the fast clearance of IgE from the blood, the tumor-to-blood ratios of anti-CSPG4 IgE were much higher than those of a non-tumor targeted IgE, suggesting that anti-CSPG4 IgE could reach its target antigen in tumors.